Back to Search
Start Over
Aurinia ditches would-be Restasis rival after phase 2/3 fail.
- Source :
- FierceBiotech; 11/2/2020, pN.PAG-N.PAG, 1p
- Publication Year :
- 2020
-
Abstract
- Aurinia and its dry eye drug started 2019 with a mixed bag of data from a head-to-head trial with Allergan's blockbuster Restasis. Now, it's unveiling results from a different trial—and they're definitely not mixed. The company is abandoning the dry eye program after it failed to beat placebo at helping patients produce more tears. [ABSTRACT FROM AUTHOR]
- Subjects :
- DRY eye syndromes
PLACEBOS
Subjects
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- FierceBiotech
- Publication Type :
- Periodical
- Accession number :
- 146829292